Cargando…
Low Pretreatment CD4(+):CD8(+) T Cell Ratios and CD39(+)CD73(+)CD19(+) B Cell Proportions Are Associated with Improved Relapse-Free Survival in Head and Neck Squamous Cell Carcinoma
The ectonucleotidases CD39 and CD73 are present on immune cells and play important roles in cancer progression by suppressing antitumour immunity. As such, CD39 and CD73 on peripheral blood mononuclear cells (PBMCs) are emerging as potential biomarkers to predict disease outcomes and treatment respo...
Autores principales: | Turner, Ross J., Guy, Thomas V., Geraghty, Nicholas J., Splitt, Ashleigh, Watson, Debbie, Brungs, Daniel, Carolan, Martin G., Miller, Andrew A., de Leon, Jeremiah F., Aghmesheh, Morteza, Sluyter, Ronald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454544/ https://www.ncbi.nlm.nih.gov/pubmed/37628721 http://dx.doi.org/10.3390/ijms241612538 |
Ejemplares similares
-
The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy
por: Jiang, Xuan, et al.
Publicado: (2023) -
Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses
por: Shevchenko, Ivan, et al.
Publicado: (2020) -
Low expression of CD39 and CD73 genes in centenarians compared with octogenarians
por: Crooke, Almudena, et al.
Publicado: (2017) -
Monitoring and characterizing soluble and membrane-bound ectonucleotidases CD73 and CD39
por: Goueli, Said A., et al.
Publicado: (2019) -
CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?
por: Battastini, Ana Maria Oliveira, et al.
Publicado: (2021)